A challenge in the clinical adoption of cell-free DNA (cfDNA) liquid biopsies for cancer 14 care is their high cost compared to potential reimbursement. The most common approach 15 used in liquid biopsies to achieve high specificity detection of circulating tumor DNA 16 (ctDNA) among a large background of normal cfDNA is to attach molecular barcodes to 17 each DNA template, amplify it, and then sequence it many times to reach a low-error 18 consensus. In applications where the highest possible specificity is required, error rate can 19 be lowered further by independently detecting the sequences of both strands of the starting 20 cfDNA. While effective in error reduction, the additional sequencing redundancy required 21 by such barcoding methods can increase the cost of sequencing up to 100-fold over 22
standard next-generation sequencing (NGS) of equivalent depth. 23
We present a novel library construction and analysis method for NGS that achieves 24 comparable performance to the best barcoding methods, but without the increase in 25 sequencing and subsequent sequencing cost. Named Proximity-Sequencing (Pro-Seq), the 26 method merges multiple copies of each template into a single sequencing read by 27 physically linking the molecular copies so they seed a single sequencing cluster. Since 28 multiple DNA copies of the same template are compared for consensus within the same 29 cluster, sequencing accuracy is improved without the use of redundant reads. Additionally, 30 it is possible to represent both senses of the starting duplex in a single cluster. The resulting 31 workflow is simple, and can be completed by a single technician in a work day with 32 minimal hands on time. 33 Introduction 50
The ability to detect rare DNA variants in a background of healthy DNA using next 51 generation sequencing (NGS) has enormous potential to impact diagnostics in oncology, 52 and prenatal testing. In cancer diagnostics, the detection of circulating tumor DNA 53 (ctDNA) among cell-free DNA (cfDNA) in peripheral blood has enabled non-invasive 54 detection and profiling of many types of cancers [1-4]. These "liquid biopsies" have been 55 shown to provide actionable information in a significant fraction of patient cases [1, 4] . 56
Initially, the promise of liquid biopsies was limited technically by the relatively high error 57
rate of NGS systems, as true ctDNA mutations were obscured by inherent errors in DNA 58 library preparation and sequencing. Modern NGS systems typically produce errors at a per-59 base rate of 10 -2 to 10 -3 [5-7], while clinically relevant mutations have been shown to be at 60 or below that level [1, 8] , making many true variants undetectable. A number of barcode-61 based (or UMI-based: Unique Molecular Identifier) error correction strategies have been 62 developed in recent years [4, [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] ] but most of these methods increase the amount of 63 sequencing required per sample. As the technical challenges of liquid biopsy assays are 64 overcome, a major challenge remaining for broad clinical adoption of liquid biopsies is the 65 increased cost associated with sequencing redundancy per sample [1] . Additionally, 66 implementation of error correction has increased assay complexity and workflow time, to 67 multiple days in many cases, introducing additional logistical barriers to clinical adoption. 68
In general, barcoding methods work by uniquely labeling (barcoding) a starting nucleic 69 acid molecule (either by ligation or PCR), targeting the analysis to a specific genomic 70 region of interest through target capture or further PCR, and then making redundant PCR 71 copies of each target ( Fig 1A) . The amplified pool of redundant copies is sequenced, after 72 which reads are grouped in silico into "families" based on their unique labels. Since each 73 label represents a unique starting molecule, a consensus sequence can be determined for 74 each read family, assuming sufficient copies are present. The typical average number of 75 copies, or reads, per family required to make a consensus is around 20 [18, 24] , which 76 represents the fold-increase in sequencing required to achieve low error rate. For example, 77 if a sequencing depth (or coverage) of 10,000 unique targets or genomes is desired for low redundancy is included. Combining barcoding with in silico 'polishing', these techniques 80 can reduce the per-base error rate to 10 -5 errors per base [18] . only occur in a smaller fraction of the reads. 20 or more reads are often required to generate 87 a software consensus for a single low-error read. (B) Pro-Seq physically links copies of the 88 same starting fragment into a single complex. Each complex is then sequenced in a single 89 cluster, producing a high-fidelity read without redundancy. 90 91 Further reduction in error rate has been achieved through a method called 'duplex 92 sequencing ' [11] . This method is similar to the barcoding scheme described above, except 93 that starting molecules are labeled with barcodes through ligation in such a way that both 94 senses of the starting molecule can be collapsed into a single barcode family, requiring true 95 variants to be present on both senses of the starting duplex. Duplex sequencing has been shown to reduce errors to below 10 -6 errors per base [25] and has the powerful ability to 97 detect and reject DNA damage and rare sources of errors such as "jackpot mutations" 98 (errors in the first cycle of PCR), which are not generally corrected in single-stranded 99 barcoding. This is especially useful when working with potentially damaged DNA such as 100 A practical limitation is the read length required to read more than two template copies in 114 the concatenated template structure, which limits the error rate achievable. Since cell free 115 DNA (cfDNA) is on average ~170bp [29] , it is only practically possible to read the single 116 copies on each end of the concatenated template with a paired-end sequencing strategy, 117 such as is available on Illumina platforms. Also, long concatenated templates are known 118 by the manufacturer to inhibit cluster generation, reducing usable sequencing clusters. 119
Additionally, in its current form, the technique is not able to create concatenated duplex 120 reads, thus requiring extra sequencing if duplex information is desired. 121
We have developed Proximity Sequencing (Pro-Seq), a library preparation method that 122 solves these challenges by physically merging both senses of read families into a single 123 cluster and using the sequencer to generate a family consensus, thus eliminating the use of 124 barcodes and redundant reads ( Fig 1B) . Here we describe the Pro-Seq method, report the 125 analytical characterization of the assay and demonstrate its utility for high accuracy liquid biopsy with significantly reduced sequencing requirements, and a simple, one day 127 workflow. 128
Proximity Sequencing (Pro-Seq) Method

129
The Pro-Seq method is illustrated for an Illumina® sequencer in Fig 1B and Fig 2, and is 130 conceptually applicable to other sequencing-by-synthesis platforms as well. In its general 131 form, the method involves linking multiple copies of a single DNA template at the 5' end 132 early in the workflow so that the sequences of all molecules in a linked complex are 133 nominally the same, with the exception of any errors made in their derivation from the 134 parent strand. The linking is arranged in such a way that both senses of the starting template 135 can be represented in a single linked complex, providing duplex information. The linked complex is then sequenced directly so that the multiple linked copies seed a 148 single sequencing cluster/colony (Fig 2) . Cluster generation proceeds as usual, except that 149 a single cluster now represents the aggregation of multiple redundant members of a family, 150 instead of a single molecule. As sequencing proceeds, errors that are low abundance within 151 an individual cluster are suppressed automatically by the sequencer's basecaller. After 152 sequencing, additional error bases are identified in silico by a drop in relative fluorescence 153 (fQ), and subsequently masked (Fig 3) . The outcome is a collapsing of multiple reads from 154 a single starting template into a single cluster, increasing the accuracy of each cluster on 155 the sequencer rather than requiring many clusters to achieve the same result. Depending on 156 the application, it is also possible to integrate unique molecular identifiers for counting 157 purposes, ensuring accurate quantification of sequenced molecules. We have developed 158 both targeted and whole genome workflows based on this concept, but the targeted 159 approach is the focus of this manuscript. Whole Genome Pro-Seq is described in S1 Fig Materials and Methods. Briefly, the simple workflow consists of three main steps: droplet 171 PCR, enzymatic cleanup and sequencing. Non-denatured dsDNA is loaded directly into 172 droplets to retain duplex information, at a concentration that yields on average zero or 173 one target template contained in each drop (ssDNA can also be sequenced in the same 174 way with low error rate, but will not benefit from duplex error correction). Each droplet 175 contains all multiplex gene specific primer sets, as well as universal linked primers with 176 sequencing adapters. After droplets are loaded, the PCR reaction is thermally cycled to 177 create linked molecules from each template-containing drop (effectively performing gene 178 specific and universal PCR simultaneously). The emulsion is then broken and un-linked 179 DNA is digested so only linked DNA remains. After quantification, the library is 180 sequenced. The workflow is rapid, as a single technician can easily process multiple 181 samples from extracted DNA to loaded sequencer in less than an 8-hour work day. 182
All data presented in this paper uses a primer linking two molecules; however, constructs 183 with up to 100 linkers have also been tested. These higher order linkers may reduce error 184
rate further than what is reported herein. 185 
Results
198
We sought to evaluate and compare the analytical specifications of Pro-Seq to existing 199 methods in order to assess its suitability for liquid biopsy applications, as many groups 200 have previously shown the clinical utility of liquid biopsy for given assay characteristics 201
[1, 2, 4, 30]. In addition, as a secondary result, we characterized the background mutation 202 frequency in cell line cfDNA standards, demonstrating that care must be taken when 203 using this source of DNA as a standard in high sensitivity assays. 204
Analytical specificity (or analytical true negative rate) is defined as the fraction of truly 205 negative samples that are called negative. It can also be defined as 1 -FPR, where FPR is 206 the False Positive Rate and in our case is defined per sample as the total number of non-207 reference bases called (regardless of abundance) divided by total bases called. This 208 metric was used to provide an absolute measure of assay performance (per base), and, 209 notably, is different than many other assay performance reports which define false 210 positive rate as the rate of inadvertently calling a mutation above a certain threshold 211 frequency [4, 18] . 212
The targeted Pro-Seq false positive rate (FPR) was measured using a 7-amplicon panel on Positive mutation detection was set to be above a threshold of 0.5 genomes, and the 237 resulting data is presented in Table 1. In the lowest abundance sample, containing an 238 average of 1.5 copies of each mutant, mutant copies were detected successfully for over 239 70% of the theoretically accessible mutations as estimated by sampling statistics. This 240 increased to 100% detection between 4.5 and 15 copies per mutant. 241 242 For ten possible mutants split between two replicates at each copy number, a mutant was 244 reported positive if greater than 0.5 copies was measured. The expected number of 245 mutants was 'corrected' based on sampling variability (independent of assay type), using 246 a binomial distribution probability that less than 0.5 mutants would be sampled for a 247 given expected number of mutant copies. 248 249 Second, we characterized analytical sensitivity by the detection threshold, using a metric 250 defined in [4] as the SNV fraction at which ≥80% of SNVs were detected above wild-251 type background. We did this by fixing the number of SNV molecules at ten, above the 252 molecular sensitivity and sampling limits, and then by increasing the number of wild-type 253 genomes to reduce the variant fraction. Cell line DNA carrying the same five known 254 mutants as presented above was titrated in duplicate into increasing amounts of wild-type 255 cell line DNA, to generate samples with the desired mutant fractions. Wild-type cell line 256 DNA with no mutant spike was also analyzed to measure background mutation levels. 257
The detection threshold was measured to be 0.003%, as the lowest mutant fraction with 258 four of five mutants detected above background. 100% of mutations were detected at 0.01% mutant fraction. Wild-type cell line samples analyzed at the same depth as the 260 0.003% replicates showed positive background detection for EGFR T790M, but the other 261 four mutants showed no background. It is important to note, especially in the case of cell 262 line DNA, that the EGFR mutation detected in the wild-type sample may be a real 263 variant. The average expected vs. average measured frequency across the five mutations 264 is shown in Fig 6, and is concordant across the tested range. Pro-Seq was also characterized by how efficiently it uses the sequencer, compared to 297 other methods. Since barcoded sequencing methods typically report the number of reads 298 required to make a consensus for each individual input template molecule, we sought to 299 compare Pro-Seq by this metric. Though Pro-Seq does not use consensus reads, there is a 300 fraction of reads that are not seeded by two or more templates, and thus a measurement of 301 the number of reads required to generate a single high fidelity read is still appropriate for 302 comparison. Sequencing efficiency was characterized by measuring the average number 303 of on-target reads required to achieve a single high fidelity read, as a function of the 304 measured cfDNA error per base. This measurement was made using the workflow 305 described in Materials and Methods, and the data is presented in Fig 8, While measuring the molecular sensitivity and detection threshold as described above, we 319 also observed the average background error rate (known mutants removed) for samples 320 containing cell line DNA was 4.6 x 10 -6 errors per base (n = 17, SD = 1.4 x 10 -6 ), nearly 321 two-fold higher and significantly different than the background rate of wild-type plasma 322 presented above (p<0.001, t-test). This measurement is consistent with common cell line ClinicalTrials.gov identifier NCT02889978). A lower cost assay with a simple workflow 336 and equivalent performance compared to conventional methods could increase both 337 clinical adoption and reimbursement for these and other applications. 338
The measured per-base cfDNA error rate of Pro-Seq (2.6 x 10 -6 ) is comparable to duplex 339 barcoding of cfDNA (3 x 10 -6 ) [18] and 10-fold better than hybrid barcoding (2 x 10 -5 ) 340
[18]. For Pro-Seq, this results in a per-base analytical specificity of 99.9997% which is 341 better than 99.998% calculated for hybrid barcoding. Other methods [4] report similar 342 specificity to Pro-Seq, but only for SNVs present at greater than 2% allele fraction, 343 missing many clinically relevant mutations. The incorporation of duplex information in 344
Pro-Seq also helps ensure that DNA damage or other early errors do not contribute 345 significantly to background error rate. This results in extremely high per-base analytical 346 specificity which enables detection of very low-level variants with high confidence, even 347 on broad panels. We suspect the analytical error rate and specificity of Pro-Seq may be 348 limited in part by real biological background, but may still improve further with 349 implementation of in silico error 'polishing'. 350
To the best of our knowledge, the Pro-Seq per-base detection threshold of 0.003% is 351 among the lowest reported. Other groups have reported comparable detection thresholds 352 when looking for multiple mutations at once [18] but this metric is not as directly 353 reflective of assay performance. Considering the practical limits of liquid biopsy assays, 354 we note that a detection threshold of 0.003% is safely below the maximum requirements 355 of nearly any imaginable blood-based application. A typical human blood sample will 356 contain on the order of a few nanograms of cfDNA per milliliter of plasma, so with a 357 detection threshold of 0.003%, the assay technical limits are not likely to limit clinical 358 performance in blood draws up to 100 mL volume, except in rare cases of extremely high important in tissue (FFPE or fresh) or other samples in cases where DNA mass is not 361 limited and information on rare variants is desired. 362
Similarly, near-single-molecule sensitivity suggests that Pro-Seq is able to capture 363 mutations present in a sample at very high efficiency, which in turn indicates that Pro-364
Seq does not suffer from the input template losses associated with barcoded duplex 365 sequencing and other similar methods. 366
The demonstrated analytical cfDNA performance of Pro-Seq is comparable or better than 367 conventional barcoding methods (including duplex methods), but is achieved with 368 significantly fewer sequencing reads (~10-fold less compared to duplex sequencing). The 369 high reads per consensus required for duplex sequencing can at least in part be attributed 370 to random sampling which is required to represent both senses of each starting template 371 with sufficient redundancy to create a consensus. When sampling randomly, many other 372 templates are sequenced unnecessarily. A less pronounced sampling effect is observed for 373 non-duplex barcoding methods that require representation of only one sense. The 374 sampling effect is confounded by any errors or chimeras formed within the UIDs 375 themselves, which create isolated barcodes and requires increased sequencing [13] . Pro-376
Seq avoids consensus read sampling by physically linking molecules, and because no 377
barcodes are required, avoids extra sequencing associated with barcode errors. 378
It should be pointed out that the sequencing redundancy for barcoding methods serves at 379 least two functions. First, it provides the necessary number of copies to call a consensus, 380 but additionally it provides assurance that each starting molecule is represented on the 381 sequencer, which is required for high sensitivity applications. If every read on a 382 sequencer was low-error, redundancy would not be required, and to minimize sequencing 383 cost each original template would ideally be sequenced only once. However, because of 384 sampling variation, aiming for 1x coverage of each template would result in dropout of a 385 significant fraction of molecules, reducing assay sensitivity. Therefore, for Pro-Seq, 386
where high accuracy individual reads are generated, a small amount of redundancy is 387 required to ensure each starting template is represented on the sequencer. Even 388 accounting for an extra three-fold redundancy, Pro-Seq requires comparable or fewer panel sizes, greater than 10-fold reduction in sequencing cost can result in a significant 392 reduction in total assay cost. As panel size increases and sequencing cost becomes a 393 larger part of the total cost, the Pro-Seq cost advantage become even more significant, on 394 the order of 10-fold. 395
In addition to lower cost, Pro-Seq also provides a workflow simplicity and speed 396 advantage, which is important for clinical adoption. In contrast to other methods which 397 require multi-day workflows for ligation, target capture and multiple PCRs (ex. cfDNA was isolated from up to 10 mL of peripheral blood per extraction. First, the blood 560 was centrifuged for 10 min at 2,000g and 4 ˚C, after which plasma was removed and spun 561 again for 10 min at 2,000g and 4 ˚C. cfDNA was isolated from each sample using the 562 QIAamp Circulating Nucleic Acid Kit (Qiagen) according to the manufacturer's 563 instructions. DNA was eluted from the column in 0.1x IDTE (Integrated DNA 564 Technologies (IDT)) in a two-step process. 100 μL of 0.1x IDTE was incubated in the 565 column for 10 min, followed by a 20,000g spin for 3 min. Incubation and spin was 566 repeated for a total elution volume of 200 μL to maximize elution yield. The full volume 567 of DNA was further cleaned up to remove any potential inhibitors using the Monarch 568 PCR & DNA Cleanup Kit (5 μg) (New England BioLabs (NEB)). The kit was used as per 569 manufacturer's instructions, except 1 mL of 2:3 binding-buffer:ethanol was added to each 570 column in place of binding buffer alone, to improve yield. Additionally, each column was 571 eluted in 15 μL of 0.1x TDTE. Extracted and purified DNA was then used directly for 572 library preparation, or in cases where library preparation did not proceed within 24 hours, 573 was frozen at -20 ˚C. 574
Following DNA extraction, the number of human genome equivalent copies in each 575 sample was measured using quantitative PCR. Two reference loci, COG5 and ALB, were 576 amplified in serial 10-fold dilutions and measured in duplicate. 577 578 
Targeted Pro-Seq Library Workflow
